Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine (Nasdaq: CMND) announced that its subsidiary Charging Robotics has launched an autonomous charging platform for robotaxis and autonomous fleets.
Clearmind owns 51% of Charging Robotics. The platform also targets automated parking facilities and transfers electricity across an air gap without physical connectors. It is designed to deliver up to 10 kW and achieve efficiency of up to 95% under specified operating conditions. Its scheduling system is designed to allocate power across vehicles and reduce peak electricity demand, with remote monitoring and centralized management.
Clearmind Medicine (CMND) announced publication in Japan of a patent application covering its 3-MMC-based approach to treating dyskinesia, a neurological movement disorder.
The application covers preventing, treating or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC. It also includes claims for combinations with N-acylethanolamines, notably Palmitoylethanolamide (PEA). Dyskinesia is characterized by involuntary movements. The applications form part of Clearmind’s ongoing collaboration with NeuroThera Labs, which integrates PEA technology into Clearmind’s psychedelic-derived therapeutic programs.
Clearmind Medicine (CMND) submitted recommendations to the FDA on patient access and potential future therapeutic use of psychedelic-derived, non-hallucinogenic compounds.
The submission responds to FDA Docket No. FDA-2026-N-7542. Clearmind recommends guidance for self-administration and potential at-home therapies, streamlined regulatory pathways, broader clinical trial access and use of Breakthrough Designation. It also calls for research collaborations with VA, DoW and HHS for alcohol use disorder and other indications.
The company says data from its Yale and Johns Hopkins trials suggest compounds designed to enhance brain adaptability without hallucinations may reduce the need for expensive supervised dosing. The submission follows its July response to an HHS information request and a September 14, 2026 briefing by its Chief of Global Impact to an FDA-convened federal panel.
SciSparc (SPRC)/b) reported that subsidiary Three U.S. patent applications have been published for combinations of lysergic acid diethylamide (LSD), ketamine and ibogaine with N‑acylethanolamines, including NeuroThera’s proprietary palmitoylethanolamide (PEA) technology. The filings describe potential therapeutic uses across mental health conditions such as depression and post‑traumatic stress disorder (PTSD), as well as pain and substance use disorders.
These applications build on a previously announced U.S. patent application for combinations of MDMA and N‑acylethanolamines targeting PTSD, anxiety and eating disorders. NeuroThera states that the maturing patent portfolio illustrates broader potential applications of its PEA technology with psychedelic compounds, and that the collaboration with Clearmind is intended to support development of safer, more effective treatments for common and growing mental‑health and substance use conditions.
Clearmind Medicine (CMND) reported publication in the United States of three patent applications covering novel combinations of LSD, ketamine and ibogaine with N‑acylethanolamines, including palmitoylethanolamide (PEA).
The applications cover potential therapeutic uses for mental health conditions such as depression and post‑traumatic stress disorder (PTSD), as well as pain and substance use disorders. The publications build on Clearmind’s collaboration with NeuroThera Labs, which integrates NeuroThera’s PEA technology into Clearmind’s psychedelic‑derived therapeutic programs and has yielded a growing portfolio of PEA‑psychedelic patent filings. Clearmind previously reported a U.S. patent application publication for MDMA combined with N‑acylethanolamines targeting PTSD, anxiety and eating disorders. The company believes its combination approach may enable effective and safer treatments by achieving therapeutic effects at lower doses, potentially improving tolerability while maintaining efficacy.
Clearmind Medicine (CMND) reported that Chief of Global Impact Mary-Elizabeth Gifford briefed a U.S. Food and Drug Administration panel at a historic psychedelic hearing in Washington, D.C. on September 14, 2026.
The FDA-convened forum, focused on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” gathered senior officials from FDA, SAMHSA, NIH, NIDA, ARPA-H and the Veterans Health Administration, with about 1,800 participants attending in person and virtually. Gifford addressed patient access, sharing insights from Clearmind’s FDA-approved clinical trial of its proprietary non-hallucinogenic neuroplastogen MEAI for Alcohol Use Disorder at Yale University Medical School and Johns Hopkins University. The company said trial findings suggest these next-generation compounds may enhance neuroplasticity without hallucinations and could reduce the need for expensive supervised dosing, potentially enabling scalable treatment through existing primary care and VA systems.
Clearmind Medicine (CMND) has enrolled the first patients with Alcohol Use Disorder in its ongoing clinical trial of CMND-100, its proprietary non-hallucinogenic psychedelic-derived candidate for AUD.
The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, representing the first administration of CMND-100 to individuals with AUD. CMND-100 has previously been evaluated at multiple doses in healthy participants as part of the company’s clinical development program. The current trial is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with Alcohol Use Disorder. The company’s chief executive officer stated that enrollment momentum is building and that progressing toward key clinical milestones may drive value for shareholders.
Clearmind Medicine (CMND) received Yale University IRB approval to begin recruiting patients for Parts B and C of its Phase I/II CMND-100 trial. This clearance enables immediate expansion of enrollment at Yale School of Medicine’s Department of Psychiatry, joining existing sites at Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center in the multicenter study.
The trial, titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects with AUD,” evaluates Clearmind’s proprietary non-hallucinogenic, MEAI-based candidate for Alcohol Use Disorder. Part A of this FDA-regulated trial met its primary endpoint of safety and tolerability, with all 24 participants across four ascending-dose cohorts completing treatment per protocol. CMND-100 showed a consistent safety profile, including at the highest dose, and no serious adverse events were observed.
Clearmind Medicine (CMND) signed a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for an aggregate purchase price of $2.5 million.
Charging Robotics develops proprietary intelligent wireless charging systems delivering up to 10 kW of continuous power for automated parking facilities, autonomous mobile platforms and robotaxi operations, where traditional plug-in infrastructure is not practical. Its systems integrate into robotic parking platforms and autonomous vehicle workflows, enabling fully automated charging without manual cable connection or conventional charging stations.
As a condition to closing, Clearmind will extend a $1.5 million loan to Charging Robotics bearing 4% annual interest, maturing three years after closing unless extended automatically if the borrower has not yet generated sufficient positive cash flow and available financing to repay. The acquisition closing is expected during the week of September 7, 2026, subject to customary conditions.
Clearmind Medicine (Nasdaq: CMND) reported that Part C Phase IIa of its double-blind, placebo-controlled Phase I/IIa trial of lead candidate CMND-100 for Alcohol Use Disorder (AUD) is now underway, with six patients enrolled to date across two Israeli centers.
Three participants were enrolled at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem, marking the first multiple-dose treatment phase in AUD patients after successful completion of the initial safety part in healthy volunteers. The four-part study evaluates single and multiple dose safety, tolerability and pharmacokinetics of CMND-100 in healthy volunteers and individuals with moderate-to-severe AUD. An independent Data and Safety Monitoring Board previously reviewed Part A data and recommended advancing the study, supporting continued clinical evaluation and progression into multiple dosing in healthy volunteers and single dosing in AUD patients.